• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by PolyPid Ltd.

    7/2/24 4:10:40 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYPD alert in real time by email
    S-8 1 ea0208116-s8_polypid.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on July 2, 2024

    Registration No. 333-           

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    PolyPid Ltd.

    (Exact name of Registrant as specified in its charter)

     

    State of Israel   Not applicable
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    18 Hasivim Street

    Petach Tikva 4959376, Israel

    (Address of principal executive offices) (Zip code)

     

    Amended and Restated 2012 Share Option Plan

    (Full title of the plan)

     

    Dikla Czaczkes Akselbrad

    President

    PolyPid Inc.

    372 Franklin Ave.

    P.O. Box 558

    Nutley, NJ 07110

    Telephone: (908) 858-5995

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Oded Har-Even, Esq.

    Howard Berkenblit, Esq.

    Sullivan & Worcester LLP

    1633 Broadway

    New York, NY 10019

    Telephone: (212) 660-3000

     

    Adv. Reut Alfiah

    Adv. Gal Cohen

    Sullivan & Worcester Tel-Aviv (Har Even & Co.)

    28 HaArba’a St. HaArba’a Towers

    North Tower, 35th floor

    Tel-Aviv, Israel 6473925

    Tel: +972 74-758-0480

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer ☐ Accelerated filer ☐
      Non-accelerated filer ☒ Smaller reporting company ☐
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    The purpose of this Registration Statement on Form S-8, or the Registration Statement, is to register 2,000,000 additional ordinary shares, no par value per share, or the Ordinary Shares, of PolyPid Ltd., or the Registrant or the Company, to be reserved for issuance under the PolyPid Ltd. Amended and Restated 2012 Share Option Plan, or the Plan, which are in addition to the 311,570 Ordinary Shares under the Plan registered on the Company’s Registration Statements on Form S-8 filed by the Registrant with the Securities and Exchange Commission, or the Commission, on June 29, 2020 (File No. 333-239517), March 31, 2023 (File No. 333-271060), and March 6, 2024 (File No. 333-277703) or, collectively, the Prior Registration Statement.

     

    This Registration Statement relates to securities of the same class as those to which the Prior Registration Statement relates and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to Instruction E of Form S-8, the contents of the Prior Registration Statement are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended.

     

    I-1

     

     

    PART II

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

     

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

      (a) The Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the Commission on March 6, 2024;
         
      (b) The Company’s reports of foreign private issuer on Form 6-K furnished to the SEC on April 30, 2024 (with respect to the first two paragraphs and the section titled “Forward-looking Statements” in the press release attached as Exhibit 99.1), May 8, 2024 (with respect to the bullet points under the section titled “Recent Corporate Highlights,” the sections titled “Financial results for the three months ended March 31, 2024”, “Balance Sheet Highlights,” and “Forward-looking Statements” and the financial statements in the press release attached as Exhibit 99.1), May 17, 2024, May 28, 2024 and June 18, 2024 (with respect to the first, second and fourth paragraphs and the section titled “Forward-looking Statements” in the press release attached as Exhibit 99.1); and
         
      (c) The description of the Registrant’s Ordinary Shares which is contained in the Registrant’s Registration Statement on Form 8-A filed on June 18, 2020 (File No. 001-38428) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as amended by Exhibit 2.4 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2023, and including any further amendment or report filed or to be filed for the purpose of updating such description.

     

    In addition to the foregoing, all documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act and all reports on Form 6-K subsequently filed by the Registrant which state that they are incorporated by reference herein, prior to the filing of a post-effective amendment which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    ITEM 8. EXHIBITS

     

    4.1   Amended and Restated Articles of Association of PolyPid Ltd., filed as Exhibit 99.1 to Form 6-K (File No. 001-38428) filed on May 8, 2023, and incorporated herein by reference.
         
    5.1   Opinion of Sullivan & Worcester Tel-Aviv (Har-Even & Co.).
         
    23.1   Consent of Kost, Forer, Gabbay & Kasierer, Certified Public Accountants (Israel), an independent registered public accounting firm and a member firm of EY Global.
         
    23.2   Consent of Sullivan & Worcester Tel Aviv (Har-Even & Co.) (included in the opinion filed as Exhibit 5.1 to this Registration Statement).
         
    24.1   Power of Attorney (included on signature page to this Registration Statement).
         
    99.1   Amended and Restated PolyPid Ltd. 2012 Share Option Plan, filed as Exhibit 99.1 to Form 6-K (File No. 001-38428) filed on May 17, 2024, and incorporated herein by reference.
         
    107   Filing Fee Table.

     

    II-1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Petach Tikva, Israel, on July 2, 2024.

     

      POLYPID LTD.
         
      By: /s/ Dikla Czaczkes Akselbrad
      Name:  Dikla Czaczkes Akselbrad
      Title:  Chief Executive Officer

     

    POWER OF ATTORNEY

     

    We, the undersigned officers and directors of PolyPid Ltd. hereby constitute and appoint Dikla Czaczkes Akselbrad our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this Registration Statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as she might or could do in person, hereby ratifying and confirming our signatures to said amendments to this Registration Statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.

     

    Name   Position   Date
             
    /s/ Dikla Czaczkes Akselbrad   Chief Executive Officer and Director   July 2, 2024
    Dikla Czaczkes Akselbrad   (Principal Executive Officer)    
             
    /s/ Jonny Missulawin   Chief Financial Officer   July 2, 2024
    Jonny Missulawin   (Principal Financial Officer and Accounting Officer)    
             
    /s/ Jacob Harel   Chairman of the Board of Directors   July 2, 2024
    Jacob Harel        
             
    /s/ Yechezkel Barenholz, Ph.D.   Director   July 2, 2024
    Yechezkel Barenholz, Ph.D.        
             
    /s/ Yossi BenAmram   Director   July 2, 2024
    Yossi BenAmram        
             
    /s/ Nir Dror   Director   July 2, 2024
    Nir Dror        
             
    /s/ Itzhak Krinsky, Ph.D.   Director   July 2, 2024
    Itzhak Krinsky, Ph.D.        
             
    /s/ Robert B. Stein, M.D., Ph.D.   Director   July 2, 2024
    Robert B. Stein, M.D., Ph.D.        
             
    /s/ Nurit Tweezer-Zaks   Director   July 2, 2024
    Nurit Tweezer-Zaks        

     

    II-2

     

     

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT

     

    Pursuant to the Securities Act, the undersigned, the duly authorized representative in the United States of the registrant has signed this registration statement or amendment thereto on July 2, 2024.

     

      PolyPid Inc.
         
      By: /s/ Dikla Czaczkes Akselbrad
        Dikla Czaczkes Akselbrad
    Director

     

     

    II-3

     

     

    Get the next $PYPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PYPD

    DatePrice TargetRatingAnalyst
    6/5/2025$9.00Buy
    Roth Capital
    6/2/2025$11.00Buy
    H.C. Wainwright
    1/28/2025$13.00Buy
    Rodman & Renshaw
    2/11/2022$23.00 → $17.00Strong Buy
    Raymond James
    9/14/2021$14.00Market Outperform
    JMP Securities
    7/30/2021$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PYPD
    SEC Filings

    View All

    SEC Form 6-K filed by PolyPid Ltd.

    6-K - PolyPid Ltd. (0001611842) (Filer)

    2/4/26 4:05:01 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PolyPid Ltd.

    SCHEDULE 13G/A - PolyPid Ltd. (0001611842) (Subject)

    1/30/26 1:02:52 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PolyPid Ltd.

    6-K - PolyPid Ltd. (0001611842) (Filer)

    12/31/25 4:01:17 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on PolyPid Ltd. with a new price target

    Roth Capital initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $9.00

    6/5/25 7:35:43 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on PolyPid Ltd. with a new price target

    H.C. Wainwright resumed coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $11.00

    6/2/25 8:53:56 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on PolyPid Ltd. with a new price target

    Rodman & Renshaw initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $13.00

    1/28/25 7:16:12 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

    PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

    1/28/26 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

    PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application ("NDA") meeting minutes from the U.S. Food and Drug Administration ("FDA") supporting the NDA submission of D-PLEX100, the Company's lead product candidate for the prevention of surgical site infections in abdominal colorectal surgeries. The FDA agreed that the Company's existing clinical data package, including results from the Phase 3 SHIELD II trial, appears adequate to support NDA submission and review. The FDA also agreed to a rolling N

    12/3/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Leadership Updates

    Live Leadership Updates

    View All

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

    PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer, effective as of August 18, 2025. Dr. Tweezer-Zaks, who has served on PolyPid's Board of Directors (the "Board") since November 2023, will step down from the Board, effective as of August 17, 2025 as she assumes this new executive role. "We are delighted to welcome Dr. Tweezer-Zaks to the executive team at this pivotal time for PolyPid following our positive Phase 3 SHIELD II trial results," said Dikla Czaczkes Aks

    8/12/25 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

    PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years. "We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physic

    11/7/23 7:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Financials

    Live finance-specific insights

    View All

    PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

    PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

    1/28/26 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness with Successful Completion of IMOH GMP Inspection Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 202

    11/12/25 7:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

    PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question o

    10/29/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    11/29/24 1:20:33 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    10/28/24 4:01:03 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care